Lizzy Lawrence

Eli Lilly's obesity drug retatrutide is being made available to one individual through the FDA's 'compassionate use' program. The article discusses this development alongside broader questions about drugmaker acquisitions and the investment potential of hair loss drugs, as covered in a podcast episode.

A man was granted compassionate-use access to an experimental GLP-1 drug developed by Eli Lilly. The exclusive report details the sole individual given special access to the obesity treatment, as covered in STAT's health policy newsletter.

Eli Lilly and the FDA have allowed one person to receive the company's obesity drug retatrutide through the FDA's 'compassionate use' program. The access was granted via an exclusive report by Lizzy Lawrence.

Makary is departing and his policies are being discussed, Kyle Diamantas is his acting replacement, and FDA reporter Lizzy Lawrence is providing insight on the topic.

FDA Commissioner Marty Makary resigned and Kyle Diamantas will step in as acting commissioner. The resignation comes after speculation and criticism of Makary's performance. Matt Herper has expressed a strongly negative opinion of Makary's tenure.

Capricor Therapeutics is suing its partner Nippon Shinyaku over the launch of its Duchenne therapy, claiming they botched preparations and created an inaccessible pricing structure. The biotech company is fighting for its promising treatment, deramiocel. This lawsuit may impact the accessibility of the treatment for patients.

Six former FDA officials shared their stories about their time at the agency and why they left during the second Trump administration. They were interviewed by STAT's FDA reporter Lizzy Lawrence. The officials included former director of the FDA's Center for Drug Evaluation and Research Richard Pazdur.